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Background: Toxoplasmosis is a worldwide infection caused by the protozoan parasite Toxoplasma gondii, which
causes chorioretinitis and neurological defects in congenitally infected newborns or immunodeficient patients. The
efficacy of the current treatment is limited, primarily by serious host toxicity. In recent years, research has focused
on the development of new drugs against T. gondii. β-Carbolines (βCs), such as harmane, norharmane and harmine,
are a group of naturally occurring alkaloids that show microbicidal activity. In this work, harmane, norharmane and
harmine were tested against T. gondii.
Findings: The treatment of extracellular tachyzoites with harmane, norharmane and harmine showed a 2.5 to 3.5-
fold decrease in the invasion rates at doses of 40 μM (harmane and harmine) and 2.5 μM (norharmane) compared
with the untreated parasites. Furthermore, an effect on the replication rate could also be observed with a decrease
of 1 (harmane) and 2 (norharmane and harmine) division rounds at doses of 5 to 12.5 μM. In addition, the treated
parasites presented either delayed or no monolayer lysis compared with the untreated parasites.
Conclusions: The three βC alkaloids studied (norharmane, harmane and harmine) exhibit anti-T. gondii effects as
evidenced by the partial inhibition of parasite invasion and replication. A dose–response effect was observed at a
relatively low drug concentration (< 40 μM), at which no cytotoxic effect was observed on the host cell line (Vero).
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The protozoan parasite Toxoplasma gondii is the etiologic
agent of toxoplasmosis, a worldwide infection affecting
500 million to 1 billion people [1]. Toxoplasmosis occurs
as an asymptomatic chronic (latent) infection. However, it
is of medical health importance because toxoplasmosis
can be dangerous or even fatal in immunocompromised
individuals because of the reactivation of a latent infection.
Congenital infection with Toxoplasma can also cause
either spontaneous abortion or birth defects [2]. In
the latter case, the active form of the parasite can cause
encephalitis and neurologic diseases and can affect the
heart, liver, inner ears, and eyes (chorioretinitis). Recently,* Correspondence: fcabrerizo@intech.gov.ar; sangel@intech.gov.ar
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reproduction in any medium, provided the orchronic toxoplasmosis has been linked with brain can-
cer, attention deficit hyperactivity disorder, obsessive-
compulsive disorder and schizophrenia [3-6].
There are effective drug regimens for toxoplasmosis
based on a combination of pyrimethamine and sulfadia-
zine, but in some cases the efficacy of the current treat-
ment is limited, primarily by serious host toxicity and/
or development of drug-resistant parasites. In patients
under immunosuppressive therapies and particularly in
those with AIDS, treatment with sulfonamides and in-
hibitors of dihydrofolate reductase (DHFR) can produce
side effects despite the preventive administration of fo-
linic acid [7,8]. Moreover, the current therapy is inef-
fective against tissue cysts [9]. Other therapies, based on
other types of drugs (clindamycin, spiramycin or atova-
quone), have been used with limited success particularly
in long-term patient management.
In recent years, research has focused on the develop-
ment of new drugs against T. gondii [10-12]. Neverthe-
less, the need to identify and evaluate new drugs basedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gondii is still evident. In this regard, β-carbolines (βCs)
represent an excellent alternative that should be thor-
oughly investigated. βCs comprise a class of alkaloids
that are widely found in nature. These alkaloids normally
occur in plants [13,14] and mammals [15-17]. βCs are a
group of heterocyclic compounds with a 9H-pyrido[3,4-
b]indole structural unit (Figure 1) [18].
βCs were originally isolated from Peganumharmala
(Zygophyllaceae, Syrian Rue), which is used as a trad-
itional herbal drug [19,20]. Among them, harmane and
tetrahydroharmane isolated from active extracts of dif-
ferent plants have been shown to have antimalarial ac-
tivity and low cytotoxicity for human cells [21-23]. In
addition, harmane and harmine have been shown a
moderate effect on promastigotes of Leishmania infan-
tum, mainly by accumulation of parasites arrested in the
S-G2/M phases of the cell cycle, whereas harmaline has
shown only anti-leishmanial activity against intracellular
amastigotes by inhibiting the PKC enzyme [24]. Lala
et al. [25] have shown that harmine is toxic for the
promastigotes of Leishmania donovani, an effect attrib-
uted to necrosis due to non-specific membrane damage.
The nifurtimox-resistant Trypanosoma cruzi LQ strain
has shown a greater sensitivity to βCs, most likely due to
inhibition of the respiratory chain of the parasite [26].
The chaperone HSP90 is an important drug target in
protozoan parasites and new drugs are actively being
sought [12,27]. In this regard, harmine was one of the
three compounds selected among approximately 4,000
small molecules that inhibited P. falciparum HSP90 by
specific competition with its ATP-binding domain. Inter-
estingly, harmine has been shown to have anti-malarial
effects in vitro and in vivo and acts synergistically
with chloroquine and artemisinin [28,29]. El Sayed
et al. [30] also reported that new enantiomers of 8-
hydroxymanzamine A (ent-8-hydroxymanzamine A) and
manzamine F (entmanzamine), isolated from Indo-
Pacific sponge, together with manzamine A, exhibit sig-
nificant activities against T. gondii and Plasmodium spp.
There are also other studies in which βCs have shown
parasiticidal and microbicidal effects that were further
revised by Cao et al. [20].N
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Figure 1 Structure of the different βCs studied: harmane, norharmanThe success of T. gondii infection relies on host cell
recognition and attachment, invasion, replication and
egress to spread throughout the host organism. There-
fore, blocking any of these processes represents a target
for new anti-Toxoplasma drugs/therapies. Our labora-
tory has gained experience in the analysis of harmane,
norharmane and harmine for different purposes in-
cluding their use as anti-viral drugs (Cabrerizo et al., un-
published results). The biological and pharmacological
effects of these βCs are attributed in part to their ability
to intercalate DNA and inhibit topoisomerase I and II,
effects that result in alterations in DNA replication and,
therefore, defects in cell cycle progress [20]. In addition,
harmine has been found to be a potent and specific in-
hibitor of cyclin-dependent kinases (CDKs), showing a
strong inhibitory effect on the growth and proliferation
of carcinoma cells [31,32]. In this work, we evaluated
these three βC alkaloids, harmane, norharmane and
harmine, for their potential as new drugs against T.
gondii, based on their ability to block invasion, replica-
tion and growth processes.
Materials and methods
Chemicals
Norharmane, harmane, harmine and sulfadiazine (Sigma-
Aldrich Co., Buenos Aires, Argentina) were of the highest
purity available (> 98%) and used without further
purification.
Stock solutions preparation and pH adjustment
βC stock solutions (approximately 2 mM) were prepared
as described elsewhere [33]. Briefly, each alkaloid was
dissolved in acid-sterilized water. Once the alkaloid was
fully dissolved, the pH of the aqueous solutions was ad-
justed to 7.4 by the addition of drops of HCl or NaOH
solutions from a micropipette. The aliquots used in the
in vitro experiments did not modify the pH of the cell
culture. Sulfadiazine was dissolved in dimethyl sulfoxide
(DMSO, Sigma-Aldrich Co.) at 22 mM.
Parasite sources, culture and manipulation
Tachyzoites of the RH strain were cultured in standard
tachyzoite conditions in vitro: Vero and human foreskinN
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e and harmine.
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tachyzoites and incubated with Dulbecco’s modified
Eagle medium (DMEM, Gibco BRL) supplemented with
10% fetal bovine serum (FBS), penicillin (100 UI/ml; Gibco
BRL) and streptomycin (100 μg/ml; Gibco BRL) at 37°C
and 5% CO2.
Invasion
Tachyzoites of the RH strain (2.5×106) were incubated
for 1 h with different doses of βCs or water (untreated)
in DMEM at 37°C. Treated and untreated tachyzoites
were added to a Vero cell monolayer, incubated for
10 min on ice and then incubated at 37°C for 1 h,
washed three times with PBS and fixed with 4% para-
formaldehyde and 0.2% Triton X-100 and analyzed byFigure 2 Effects of harmane, norharmane and harmine on parasite in
treated for 1 h with different doses of the βCs, washed and allowed to inv
incubated with murine anti-SAG1 antibody. The secondary antibody used w
of parasitophorous vacuoles (PVs) per field was counted. Fifty fields selecte
treated for 24 h with different doses of the βCs, fixed and immunostained
counted. Fifty fields selected at random were counted in duplicate. In total
panels are representative of three independent experiments. All the experiimmunofluorescence using murine anti-SAG1 antibody
(SAG1: T. gondii surface antigen 1, 1:100 dilution)/Alexa
Fluor 594-conjugated goat anti-mouse (1:4,000 dilution;
Invitrogen, Argentina). In each experiment, 50 fields
were analyzed and the number of tachyzoites per field
was counted. Only fields with a similar number of host
cells were considered for the experiments. The mean
numbers of tachyzoites in each field plus the standard
deviation were plotted using Prism GraphPad software.
Replication and growth analysis
The replication rate was determined by incubating the
tachyzoites (2.5×106) with Vero cell monolayers, fol-
lowed by 10 min of incubation on ice, then 1 h at 37°C
and washing three times with PBS. Finally, the tachyzoitesvasion and replication. A. Extracellular tachyzoites (2.5×106) were
ade Vero cells monolayers for 1 h at 37°C, and then fixed and
as Alexa Fluor 594 goat anti-rabbit. For each treatment, the number
d at random were analyzed in duplicate. B. Infected monolayers were
with anti-SAG1 antibody. The number of tachyzoites inside the PV was
, approximately 1000 PVs per dose were analyzed in A and B. These
ments presented similar results.
Figure 3 Analysis of the toxic effect of harmane, norharmane
and harmine on T. gondii growth. Human foreskin fibroblast (HFF)
monolayers were infected with fresh tachyzoites (2.5×104) for 1 h
and incubated with different doses of βCs and followed by
microscope observation until monolayer lysis (cell lysis in
combination with extracellular tachyzoites). Data are presented as
the day post-infection (p.i.) on which complete monolayer lysis was
observed by microscope visualization. The panel is representative of
three independent experiments performed in duplicate. All the
experiments presented similar results. Sulfadiazine (5 mM) was used
as a control of T. gondii growth inhibitory drugs and showed no
monolayer lysis at day 10 p.i.
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with DMEM, 5% FBS and different doses of βCs or water
(untreated). After the infected monolayers were fixed, they
were immunolabeled with murine anti-SAG1 antibody/
Alexa Fluor 594-conjugated goat anti-mouse antibody
(Invitrogen, Argentina) and the number of tachyzoites per
parasitophorous vacuole (PV) were counted. Fifty fields
were counted in duplicate. Approximately 1000 PVs were
counted at each dose. Data are presented as a percentage
of PVs that contained a geometric progression (e.g. 1, 2, 4,
8 and so on) of tachyzoites per PV.
To analyze parasite growth, human foreskin fibroblast
(HFF) monolayers were incubated with 2×104 tachy-
zoites as above mentioned. Because tachyzoite growth is
destructive to cell monolayers, infected cultures were
followed daily by inverted microscope visualization until
complete monolayer lysis along with the presence of
extracellular tachyzoites or complete (host cell/tachy-
zoites) destruction.
Results and discussion
To analyze the effect of harmane, norharmane and har-
mine alkaloids on the ability of T. gondii to infect host
cells, 2.5×106 extracellular tachyzoites (almost all com-
prising a G1 arrested form of the parasite) were incu-
bated for 1 h with different doses (0 to 100 μM) of each
βC. This dose range was chosen because it was previ-
ously shown that βCs and especially harmine induce
apoptosis and necrosis, and inhibit proliferation of eu-
karyotic cells at concentrations higher than 40 μM [34].
Moreover, for some eukaryotic cell lines, such concen-
trations are cytotoxic [32]. Therefore, the selected βC-
concentration range was chosen to avoid any secondary
effect on the host cell line (Vero) that could interfere
with the analysis of the invasion capability of the
tachyzoites. The results plotted in Figure 2 (A) show that
the three βCs studied have an inhibitory effect on para-
site invasion in a dose-dependent manner. Norharmane
exhibited its maximum effect at 2.5 μM whereas har-
mane and harmine had the highest parasiticidal effect at
40 μM (Figure 2A). The invasion rate of tachyzoites
treated with βCs at the doses mentioned before showed
a 3.5- (harmane), 2.5- (norharmane) and 3.1- (harmine)
fold decrease compared with the untreated tachyzoites.
Because this assay does not differentiate if the compo-
nents affect the invasion process of the tachyzoites or
the attachment process, we can only conclude that the
decrease in the number of tachyzoites per field could be
caused by an inhibitory effect on invasion, or attach-
ment, or both.
To determine whether these βCs have any inhibitory
effect on the parasite cycle process, we measured the
ability of intracellular-treated parasites to replicate. Be-
cause tachyzoites replicate only within the host cell by aprocess called endodyogeny, every round of replication
results in a geometric duplication of the parasite number
per PV (e.g. 1, 2, 4, 8 and so on) [35]. Monolayers of
Vero cells were infected with 2.5×106 of fresh tachy-
zoites to allow for the formation of PVs. Subsequently,
the infected monolayers were washed and incubated at
37°C for 24 h in the presence of different doses of βCs
(0 to 40 μM) (Figure 2B). Every PV was generated from
one parasite; therefore, the number of tachyzoites inside
the PV indicates the number of replication events. The
panel shows the percentage of PVs that presented differ-
ent numbers of tachyzoites. Harmane showed a slight in-
hibitory effect starting at 25 μM, resulting in a delay of
one round of replication compared with the untreated
parasites. Harmine and norharmane had a stronger in-
hibitory effect on parasite replication than harmane, be-
cause their effect was more pronounced at 25 μM, at
which concentration the replication rate was delayed by
two rounds (Figure 2B). Doses of norharmane lower
than 5 μM did not show any effect on parasite replica-
tion (Additional file 1: Figure S1).
Toxoplasma gondii growth is the result of repeated
cycles of host cell invasion, replication and egress,
resulting in cell monolayer destruction in vitro. Because
we observed a low rate of parasite entry and tachyzoite
replication in the host cell, we expected a low rate of
parasite growth. To analyze for this effect, HFF mono-
layers were infected with fresh tachyzoites, washed and
incubated with the different doses of the βCs until the
complete monolayer was lysed. HFF monolayers were
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treated parasites. For βC-treated monolayers, a delay in
the time of complete lysis could be observed (Figure 3).
As shown in Figure 3, harmine was shown to affect
parasite growth at 40 μM. Infected monolayers treated
with 5 mM of sulfadiazine did not show cell lysis during
the 10 days of incubation (data not shown).
Our results demonstrate that the three βCs studied in
this work have anti-T. gondii effects on both host cell in-
vasion and replication processes and, consequently, on
parasite growth. Particularly, harmine was shown to be
the most active drug because it showed the strongest in-
hibitory effect on parasite replication and growth. In a
recent study [25], it has been observed that harmine
shows anti-leishmanial activity in part due to cell death
attributed to non-specific membrane damage. In our
hands, the highest dose (40 μM) of βCs affected neither
the cell integrity nor the viability of the parasite. The
entry of the tachyzoite into the host cell is an ATP-
consuming process that includes the glideosome/myosin
motor [36]. In this sense, some βCs have shown an in-
hibitory effect of the respiratory chain [26,37]. It is pos-
sible that parasite fitness is decreased because of a
failure of mitochondrial functions. Our analysis did not
allow us to distinguish which process (es) these drugs
were affecting (attachment and/or invasion). Therefore,
the βCs could be interfering with several metabolism
pathways other than those related to attachment/inva-
sion of the host cell, resulting in an impairment of these
processes. Further analysis should be performed to eluci-
date which process/es is/are involved.
As mentioned above, βCs are considered to affect cell
cycle. The tachyzoite is the highly replicative stage of T.
gondii, a process that only occurs inside the host cell
[38]. It is well known that these drugs can bind to DNA
[39] and induce DNA damage [40] as well as inhibit
topoisomerases I and II. These facts can contribute to
the replication-associated DNA stress, affecting the cell
replication rate [41,42]. Harmine also affects Plasmo-
dium infection through its interaction with parasite
HSP90, a recognized drug target against malaria [12,29].
The effect of this (or these) βC(s) on parasite replication
could also involve the inhibition of Toxoplasma HSP90
functions. In fact, T. gondii HSP90 has been suggested as
a key molecule in parasite replication [43]. Future stu-
dies should be performed to assess the interaction be-
tween these alkaloids and T. gondii topoisomerases and/
or HSP90 protein and evaluate if these drugs can affect
parasite cell cycle progression.
In conclusion, we have demonstrated that the three βC
alkaloids studied (norharmane, harmane and harmine) ex-
hibit anti-T. gondii effects. Interestingly, the effect on
parasite invasion and replication occurred at low doses
(below 40 μM), at which these alkaloids did not show anytoxic effects on Vero and HFF cells used in our experi-
ments [32,34]. However, βCs have been shown to inhibit
some enzymes associated with mental disorders and could
produce behavioral modifications, including hallucinogens
in treated people [20]. This issue should be considered to
determine in vivo doses [44]. Moreover, on the basis of
the current knowledge [44], it would be possible to design
novel harmine derivatives to avoid collateral effects with-
out changing or even increasing the parasiticidal effect.
Future studies should be performed to further elucidate
the mechanism for their anti-T. gondii activity.
Additional file
Additional file 1: Figure S1. Effect of norharmane on parasite invasion
and replication. The analysis was similar to that mentioned in the
Figure 3 legend, except that the drug doses were 0, 1, 2.5 and 5 μM.
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